Instand-NGS4P Partnering Platform_20210525-test
Company Name | Country | PROVIDING solution for Lot No. | SEEKING solution for Lot No. | Short description of your proposed solution | Short description of your partnering needs | Contact Person | Presentation and/or recording | |
---|---|---|---|---|---|---|---|---|
AIT Austrian Institute of Technology GmbH | Austria | Lot 1 | (Targeted) DNA methylation sequencing, short NAs, exosomes, preanalytics, Library prep | Target enrichment companies, sequencing solution providers | Christa Noehammer | christa.noehammer@ait.ac.at | ||
Bahia Software | Spain | Lot 4 | Lots 1,2,3,4 | Bahia Software has significant experience developing software platforms for hospitals and research organizations. Bahia Software has proprietary platform technologies for Tumour Boards and is currently working in an R&D project to faciltate reporting to health professionals from Liquid Biopsy analysis. Bahia Software may also contribute with its accumulated knowledge and experience in PCP projects at european level. We have leaded and succesfully participated in two european PCP calls, very similar to InstandNGS4P. | No specific partnering needs. Very open to collaborate with organizations more interested in Lots 1, 2 and 3 | Sergio Gomez | sergio.figueiras@bahiasoftware.es | |
BC Platforms | Sweden | Lot 4 | Modular Genomic Data management and -Analysis solution for automation of Genomic data production from Raw data to actionable report. Integration of various secondary analysis pipelines, QC and variant interpretation/reporting tools from partners. | Partners for secondary analysis, QC, variant interpretation and actionable reporting are welcomed. BC Platforms provide the ovarall workflow from raw data to these integrated reports in a CE-IVDR solution established on the market. Open for customization and integration to our modular offering. | Henrik Plym-Forshell | henrik.plym-forshell@bcplatforms.com | ||
DNV | Norway | Lot 4 | Risk mitigation and quality assurance | Looking to partner with providers of analysis software, reagents, sequencers etc. to ensure pipelines, computing infrastructure etc. is implemented safely and responsibly. | Courtney Nadeau | courtney.david.nadeau@dnv.com | ||
Euformatics | Finland | Lot 3 | Clinical NGS variant interpretation and quality control software | Secondary analysis, kit providers, sequencer manufacturers | Tommi Kaasalainen | tommi.kaasalainen@euformatics.com | ||
fragmentiX Storage Solutions GmbH | Austria | Lot 3 | Trusted data environment by using SECRET SHARING with fragmentiX CLUSTER appliances | Looking for partners, resellers, customers | Werner Strasser | ws@fragmentix.com | ||
Geneyx Genomex Ltd | Israel | Lot 3 | An AI-driven platform enables accurate analysis and interpretation of Whole Genome Sequencing (WGS) data. Produces rapid diagnosis at the highest diagnostics yields: >65%. Automated Phenotype – Genotype association – connecting disease symptoms to causal genes. The impact: Faster and better clinical diagnosis and distilling novel findings for targeted and personalized therapeutics. | We may want to partner with more clinical genetic databases | Raviv ITZHAKY | raviv@geneyx.com | ||
Genuity Science | Ireland | Lot 1,2,3,4 | Lot 1,2,3,4 | Genuity Science is a CAP accredited genomics facility and has proven competencies in a range of capabilities including sample handling and processing (blood, saliva, tissue and tissue blocks) for genomic WGS analysis. Our organisation has automated and semi-automated bioinformatic pipelines for generation of a variety of reports. We have an end to end integrated genomic lab service delivery platform. | We are seeking partners potentially in the area of pre-analytics and library prep and also in the area of integrated reporting. We have the ability and desire to partner across all lots. We have a strong sample handling, NGS and bioinformatic delivery platform already established but would be keen to partner up to bring innovation not only to the project but also into our facility through collaboration. The area of least development for us is around the clinical decision support. | David Kavanagh | david.kavanagh@genuitysci.com | |
HTG Molecular Diagnostics | Germany | Lot 1,2,4 | Extraction-free Transcriptome and RNA-Panel Library Prep and Data Analysis Solution | We are interested in partnering with Lot 2 and Lot 4 providers and also with QC control providers in Lot1. Looking forward to a great partnership! | Selina Gaertner | sgaertner@htgmolecular.com | ||
iCellate Medical | Sweden | Lot 4 | End-to–end cancer NGS solution with strict adherence to clinical guidelines in ISO15189 accredited laboratory based on innovative sample types and analyses | University clinic with cancer patient management ready to merge Multidisciplinary Cancer Conference (MCC) with Molecular Tumor Board (MTB) to provide integrated management decision support | Christer Ericsson | christer.ericsson@icellate.se | ||
Integrated DNA Technologies | Germany | Lot 1 | Lot 1 | We offer highly innovative solutions for NGS library preparation (DNA/RNA) of challenging clinical samples, targeted enrichment (hybridization capture and amplicon sequencing) and normalization. We are also partnering with suppliers for extraction of nucleic acids and automation. | We are looking for providers of products in areas: pre-analytics (collection, storage and transport of specimen), QC of nucleic acids (assessment of amount, purity, integrity, fragment size distribution of NA and tumor content), QC of library prepped DNA (quantification and size distribution) and reference materials. | K. Julia Duda | kduda@idtdna.com | |
LGC Seracare | Germany | Lot 1 | Multiplexed biosynthetic reference materials in gDNA/RNA, FFPE and ctDNA format, including custom solutions and imuno-oncology | We would like to partner with a provider of nucleic acid extraction, library prep and target enrichment solutions requiring reference materials for analytical validation and CE-IVD readiness of the platform. | Krystyna Nahlik | krystyna.nahlik@lgcgroup.com | ||
Maxeler Technologies | UK | Lot 3,4 | Fast and efficient processing of sequencing data, explainable AI for drug selection, integrated in secure data analysis and collaboration platform. | Partners in Lot 3 & 4 that are in need for accelerated sequence alignment algorithms, improved AI-based decision making for drug selection, or a platform for secure data sharing, analysis and dashboarding. | Tobias Becker | tbecker@maxeler.com | ||
Micronoma | USA | Lot 4 | Microbiome Aware Liquid Biopsy | We would like to partner with company specialized in reporting results to patients and clinicians. | Sandrine Miller-Montgomery | sandrine.miller@micronoma.com | ||
Molecular Health | Germany | Lot 4 | MH Guide is a NGS platform independent interpretation solution of NGS data. | Thomas Holtrup | thomas.holtrup@molecularhealth.com | |||
Molecular Health | Germany | Lot 4 | MH Guide quickly and accurately identifies and interprets genetic variants in tumors. The MH Guide report helps treatment providers choose therapy options and clinical trials that match the cancer patients molecular profile. MH Guide is an IVD medical device approved in the EU. | Katrin Stecker | katrin.stecker@molecularhealth.com | |||
Oncompass Medicine | Hungary | Lot 4 | Multiparameter-based digital drug-assignment for treatment planning in precision oncology. | Partnering preferred with an ESCAT- or other single biomarker-based reporting solution, which represents the standard-of-care in reporting. This could be complemented with the innovative multiparametric digital solution of Oncompass Medicine. | Barbara Vodicska on behalf of Istvan Petak | barbara.vodicska@oncompassmedicine.com | ||
Roche | Germany | Lot 4 | Robert Bulte | ROBERT.BULTE@ROCHE.COM | ||||
Roche Diagnostics | Germany | Lot 4 | Navify Mutation Profiler – a clinical decision support tool | seamless integration of decision support tools & molecular tumor boards in a routine diagnostic process | Gerrit Schramm | gerrit.schramm@roche.com | ||
Semmelweis University | Hungary | Lot 4 | Miklos Garami | miklos.garami@gmail.com | ||||
University Medical Center Groningen | The Netherlands | Lot 4 | not a solution provider, but end user | Academic partner for validation of tools for variant interpretation and reporting, and interaction between MTBs | Leon van Kempen | l.van.kempen@umcg.nl |